MarketCap
Facebook
X
Telegram
Alpine Immune Sciences Balance Sheet 2023-2011 | ALPN
Brief overview of Alpine Immune Sciences's assets and capital
This overview follows the five latest available annual observations between 2019 and 2023.
Assets reached $379.9 million, compared with $54.1 million at the beginning. Growth of +602.2% and CAGR near 62.8% show active expansion.
Liabilities grew more slowly than assets: +110.9% versus +602.2%. Expansion relied more on equity, improving funding quality.
The equity ratio reached 86.3% from 54.5%. A high capital share reduces dependence on liabilities.
Negative net debt of -$34 million means cash holdings are larger than debt obligations.
Cash equals 11.6% of the balance sheet, compared with 29.8% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$256.1 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Alpine Immune Sciences shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Alpine Immune Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-34 M | - | -63.9 M | -26.7 M | -11.2 M | -6.51 M | -2.97 M | -11.7 M | -25 M | -27.8 M | 12.3 M | - | - |
Long Term Debt |
9 M | - | 3.38 M | 7.6 M | 4.51 M | 2.16 M | 4.04 M | 113 K | - | - | 13.3 M | - | - |
Long Term Debt Current |
912 K | 756 K | 617 K | 655 K | 418 K | 2.05 M | 995 K | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 15.9 M | 2.16 M | 4.41 M | - | - | 41.9 M | 91.4 M | - | - |
Total Current Liabilities |
42 M | 58 M | 69.8 M | 41.2 M | 8.68 M | 8.13 M | 1.9 M | 2.4 M | 4.42 M | 2.42 M | - | - | - |
Total Liabilities |
51.9 M | 107 M | 135 M | 81.9 M | 24.6 M | 10.3 M | 6.3 M | 2.52 M | 4.42 M | 44.3 M | 95.4 M | - | - |
Deferred Revenue |
16.3 M | 35.6 M | 51.8 M | 31.6 M | 1.44 M | - | 277 K | 2.01 M | - | - | - | - | - |
Retained Earnings |
-256 M | -224 M | -166 M | -116 M | -87.9 M | -46.1 M | -9.38 M | -1.6 M | -149 M | -126 M | -111 M | - | - |
Total Assets |
380 M | 287 M | 256 M | 144 M | 54.1 M | 54.9 M | 85.2 M | 12.6 M | 87.9 M | 28.5 M | 4.13 M | - | - |
Cash and Cash Equivalents |
43.9 M | 13.4 M | 67.9 M | 35 M | 16.1 M | 10.7 M | 8 M | 11.8 M | 25 M | 27.8 M | 1.1 M | - | - |
Book Value |
328 M | 179 M | 121 M | 62.2 M | 29.5 M | 44.6 M | 78.9 M | 10.1 M | 83.5 M | -15.8 M | -91.3 M | - | - |
Total Shareholders Equity |
328 M | 179 M | 121 M | 62.2 M | 29.5 M | 44.6 M | 78.9 M | -1.46 M | 83.5 M | -15.8 M | -91.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.7 M | 9 M | 9.29 M | 9.56 M | 1.6 M | 10.1 M | - | 1.02 M | 2.21 M | 3.38 M | 4.55 M | 5.71 M | 6.46 M | 7.6 M | 8.74 M | 9.87 M | 8.17 M | 4.51 M | 4.89 M | 1.19 M | 1.67 M | 2.16 M | 2.63 M | 3.1 M | 3.57 M | 4.04 M | 4.5 M | 4.04 M | 4.04 M | 113 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
40.9 M | 51.9 M | 78.9 M | 83.4 M | 92.6 M | 107 M | 110 M | 116 M | 119 M | 135 M | 111 M | 116 M | 76.7 M | 81.9 M | 86.6 M | 86.5 M | 25 M | 24.6 M | 29.9 M | 24.7 M | 10.5 M | 10.3 M | 9.52 M | 6.58 M | 6.82 M | 6.3 M | 7.81 M | 6.3 M | 6.3 M | 2.52 M | 2.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
10.2 M | 16.3 M | 30.1 M | 37.3 M | 40.4 M | 35.6 M | 46.2 M | 42.9 M | 51.8 M | 51.8 M | 48.1 M | 49 M | 34.5 M | 31.6 M | 28.5 M | 23.7 M | 344 K | 1.44 M | 2.07 M | 2.11 M | 1.44 M | - | - | - | 240 K | 277 K | 405 K | 277 K | - | 2.01 M | 2.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-274 M | -256 M | -262 M | -250 M | -237 M | -224 M | -205 M | -192 M | -174 M | -166 M | -151 M | -138 M | -127 M | -116 M | -110 M | -103 M | -93.5 M | -87.9 M | -81.8 M | -70.3 M | -58.5 M | -46.1 M | -34.9 M | -22.8 M | -14.9 M | -9.38 M | -5.07 M | -193 M | -189 M | -1.6 M | -173 M | -165 M | -157 M | -149 M | -142 M | -136 M | -149 M | -126 M | -126 M | -126 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
374 M | 380 M | 241 M | 253 M | 262 M | 287 M | 292 M | 216 M | 234 M | 256 M | 233 M | 160 M | 130 M | 144 M | 154 M | 103 M | 49.8 M | 54.1 M | 64.7 M | 70.1 M | 67.1 M | 54.9 M | 64.5 M | 73.1 M | 80.7 M | 85.2 M | 90.8 M | 49.6 M | 53 M | 12.6 M | 67.3 M | 74.6 M | 80.9 M | 87.9 M | 93.8 M | 101 M | 87.9 M | 28.5 M | 28.5 M | 28.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
33 M | 43.9 M | 19 M | 34.1 M | 14.5 M | 13.4 M | 127 M | 24.4 M | 34.9 M | 67.9 M | 76.1 M | 18.8 M | 12.6 M | 35 M | 141 M | 88.2 M | 24.4 M | 16.1 M | 17.4 M | 15.5 M | 41.4 M | 10.7 M | 11.5 M | 3.57 M | 7.45 M | 8 M | 12 M | 27.5 M | 12.9 M | 11.8 M | 16.2 M | 15.4 M | 16 M | 25 M | 57.6 M | 101 M | 25 M | 27.8 M | 27.8 M | 27.8 M | - | 1.1 M | - | - | - | 4.7 M | - | - | - | - | - | - | - |
Book Value |
333 M | 328 M | 162 M | 169 M | 170 M | 179 M | 182 M | 99.5 M | 115 M | 121 M | 123 M | 43.8 M | 53.3 M | 62.2 M | 67.5 M | 16.2 M | 24.9 M | 29.5 M | 34.8 M | 45.4 M | 56.6 M | 44.6 M | 55 M | 66.5 M | 73.9 M | 78.9 M | 83 M | 43.3 M | 46.7 M | 10.1 M | 64.8 M | 74.6 M | 80.9 M | 87.9 M | 93.8 M | 101 M | 87.9 M | 28.5 M | 28.5 M | 28.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
333 M | 328 M | 162 M | 169 M | 170 M | 179 M | 182 M | 99.5 M | 115 M | 121 M | 123 M | 43.8 M | 53.3 M | 62.2 M | 67.5 M | 16.2 M | 24.9 M | 29.5 M | 34.8 M | 45.4 M | 56.6 M | 44.6 M | 55 M | 66.5 M | 73.9 M | 78.9 M | 83 M | 46.1 M | 49.2 M | -1.46 M | 62.1 M | 68.7 M | 76.4 M | 83.5 M | 89.4 M | 95.1 M | 83.5 M | -15.8 M | -15.8 M | -15.8 M | - | -91.3 M | - | - | - | -75.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Alpine Immune Sciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
